Enterprise Value
106.2M
Cash
95.28M
Avg Qtr Burn
-4.802M
Short % of Float
5.84%
Insider Ownership
11.13%
Institutional Own.
17.85%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Approved Quarterly sales | ||
AZSTARYS (KP415) (serdexmethylphenidate and dexmethylphenidate) Details Attention deficit hyperactivity disorder | Approved Quarterly sales | |
Arimoclomol (Heat-Shock Protein (HSP) amplifier) Details Rare diseases, Rare genetic disease, Methanol poisoning | NDA Resubmission | |
KP1077, (serdexmethylphenidate, SDX) Details EDS in Idiopathic Hypersomnia
Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 2 Data readout | |
KP879 (Methylphenidate) Details Stimulant Use Disorder | Phase 1 Update | |
KP1077, (serdexmethylphenidate, SDX) Details Sleeping disorder, Narcolepsy | Phase 1 Initiation |